|
The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia |
Jan 2021 |
Seminars in Hematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Paroxysmal Nocturnal Hemoglobinuria |
Jan 2024 |
StatPearls |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms |
Jul 2019 |
Surgical Pathology Clinic |
Myelodysplastic Syndromes (MDS) |
|
Epidemiology and Pathogenesis of Myelodysplastic Syndrome |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Overview of the Management of Higher-Risk Myelodysplastic Syndromes |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment |
May 2023 |
The Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency |
Oct 2019 |
The Journal of Clinical Investigation |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial |
Jun 2019 |
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria |
Mar 2021 |
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
